Adrenaclick™ auto-injector contains 1.1 mL epinephrine injection, USP (1 mg/mL), from which one dose of either 0.15 mg (0.15 mL) or 0.3 mg (0.3 mL) each is available for use by injection. The dose is administered by autoinjection after the patient prepares and fires Adrenaclick™ as directed. The remaining volume is not available for use and should be discarded.
Adrenaclick (epinephrine injection, USP) is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Adrenaclick is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section).
Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Adrenaclick is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care.
Media Articles Related to Adrenaclick (Epinephrine)
Adrenaline: The Best and Worst of Drugs (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2014.08.23]
(MedPage Today) -- What's the place for epinephrine/adrenaline in the cardio toolbox if evidence is showing worse outcomes?
Published Studies Related to Adrenaclick (Epinephrine)
A comparison of the efficacy of 4% articaine with 1:100,000 epinephrine and 2%
lidocaine with 1:80,000 epinephrine in achieving pulpal anesthesia in maxillary
teeth with irreversible pulpitis. 
anesthesia in maxillary teeth with irreversible pulpitis... CONCLUSIONS: There was no significant difference in efficacy between 4% articaine
Triple-blind randomized clinical trial of time until sensory change using 1.5%
mepivacaine with epinephrine, 0.5% bupivacaine, or an equal mixture of both for
infraclavicular block. 
by 20% or more versus 0.5% bupivacaine alone (bupivacaine)... CONCLUSIONS: Mixing 1.5% mepivacaine (with epinephrine) with 0.5% bupivacaine
Influence of intranasal epinephrine and lidocaine spray on olfactory function tests in healthy human subjects. [2011.12]
Objective. Although topical decongestants and anesthetics are widely used in preparation for nasal endoscopy, no controlled trials have evaluated the effects of these agents on olfaction.Neither topical intranasal phenylephrine nor lidocaine use affected the results of the olfactory test, even when the agents were used in combination.
Effect of the Addition of Vasopressin or Vasopressin Plus Nitroglycerin to Epinephrine on Arterial Blood Pressure during Cardiopulmonary Resuscitation in Humans. [2011.11]
Background: Infusion of a vasopressor during cardiopulmonary resuscitation (CPR) in humans increases end decompression (diastolic) arterial blood pressure, and consequently increases vital organ perfusion pressure and survival.
Vasopressin rescue for in-pediatric intensive care unit cardiopulmonary arrest refractory to initial epinephrine dosing: A prospective feasibility pilot trial. [2011.09.15]
OBJECTIVES:: To assess the feasibility of a large, randomized controlled trial of combination epinephrine-arginine vasopressin for in-pediatric intensive care unit cardiopulmonary arrest refractory to initial epinephrine dosing... CONCLUSIONS:: These pilot data provide support for a larger randomized controlled trial of arginine vasopressin therapy during cardiopulmonary resuscitation for in-hospital pediatric cardiac arrest.
Clinical Trials Related to Adrenaclick (Epinephrine)
Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation [Recruiting]
Trial of Vasopressin and Epinephrine to Epinephrine Only for In-Hospital Pediatric Cardiopulmonary Resuscitation [Recruiting]
Cardiac arrest has a very poor prognosis, especially with prolonged efforts at
resuscitation, and unfortunately, survivors are often severely neurologically impaired. CPA
in children is often the result of a prolonged illness rather than a sudden, primary cardiac
event as is frequent in adults. This necessitates that resuscitation research must be
conducted separately for pediatric and adult patients. Authorities currently endorse the
use of epinephrine for restoring spontaneous circulation based on its ability to maintain
diastolic blood pressure and subsequent blood flow to the heart during resuscitation.
However, human studies have shown no clear survival benefit of epinephrine and have
elucidated concerning adverse effects. Recently, both the European Resuscitation Council and
the American Heart Association have recognized the use of vasopressin as a promising
vasoconstrictor and an alternative or adjunct to epinephrine in the resuscitation of adults.
Vasopressin causes profound vasoconstriction without the adverse effects of epinephrine and
is associated with improved blood flow to the heart and brain. This increased cerebral
blood flow has been associated with better neurologic outcome in animal studies. In light of
compelling animal and human studies of combined vasopressin and epinephrine, pediatric
trials are indicated for vasopressin usage in pediatric CPR. This study will evaluate the
addition of the administration of vasopressin to standard advanced CPR therapy (epinephrine
alone) for pediatric patients that experience in-intensive care unit CPA to assess for
improved time to return of spontaneous circulation (ROSC), survival to 24 hours, survival to
hospital discharge, and neurologic outcome. When a patient experiences a CPA, standard
Pediatric Advanced Life Saving (PALS) protocols as endorsed by the American Heart
Association will be initiated. This will include receiving epinephrine as the first
vasopressor medication. Patients will then be randomized to receive vasopressin (treatment
group) or epinephrine (control group) as the second vasopressor medication, if needed. If
more then two doses of vasopressor medication is required in either group, epinephrine will
be administered according to the PALS algorithm until the end of the event. All CPA events
meeting inclusion criteria will be entered into the National Registry of Cardiopulmonary
Resuscitation (NRCPR) Database, which tracts all CPA events at Children's Medical Center
Dallas. Prior to commencement of the RCT, a pilot trial of 10 patients will be completed to
assess preliminary safety, feasibility, and effectiveness of combination
epinephrine-vasopressin for pediatric in-intensive care unit CPA refractory to initial
epinephrine dosing. All pilot patients will receive vasopressin as the second vasopressor
Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics [Recruiting]
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine
Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled
epinephrine (epinephrine-d3) to differentiate the administered drug from the endogenous
epinephrine, in healthy male and female adult volunteers. The current study is designed for
a more thorough evaluation of the E004 Pharmacokinetics. Safety of E004 will also be
evaluated, under augmented dose conditions.
Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients [Recruiting]
This clinical study evaluates the 12-week efficacy and safety of Epinephrine HFA Inhalation
Aerosol HFA the proposed HFA formulation of metered dose inhaler (MDI) of Epinephrine, in
comparison to a Placebo-HFA control MDI and the currently marketed Primatene® Mist
(epinephrine CFC inhaler), in adolescent and adult subjects with asthma.
The Effect and Safety of Low Dose Nebulized Epinephrine in Croup [Not yet recruiting]
Croup is common illness presenting emergency department with dyspnea. The main treatment for
croup is nebulized L-epinephrine and steroid. The study for the dose of nebulized
L-epinephrine is restricted that the study of comparision between racemic epinephrine and
The investigators conducted this study to compare the effectiveness of low dose
L-epinephrine with conventional dose L-epinephrine.
Page last updated: 2014-08-23